Streetbeat News

Stock Prices

VITL

Vital Farms (NASDAQ:VITL) reported Q2 2024 GAAP EPS of $0.36, beating the $0.20 estimate by 80%. Sales were $147.388M, surpassing the $138.425M estimate by 6.48% and marking a 38.46% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:23 am

XMTR

Xometry (NASDAQ:XMTR) reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.01) beating the $(0.12) estimate and sales of $132.595 million surpassing the $128.648 million estimate. This represents a 19.45% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:23 am

BETR

Better Home & Finance shares are trading lower after the company reported Q2 financial results and announced a 1-for-50 reverse stock split.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:22 am

ASPN

Aspen Aerogels shares are trading higher after the company reported better-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:21 am

CGTX

Cognition Therapeutics (NASDAQ:CGTX) reported a Q2 2024 GAAP EPS of $(0.18), beating the analyst consensus estimate of $(0.24) by 25%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:21 am

HROW

Harrow shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:21 am

BMBL

Bumble shares are trading lower after the company reported worse-than-expected Q2 revenue results. Additionally, multiple firms downgraded their ratings and price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

BRAG

Bragg Gaming announced that it is currently tracking to the lower end of its FY24 revenue guidance range of $109.1M to $116.6M, with an estimate of $113.45M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

ALDX

Aldeyra Therapeutics shares are trading higher after the company achieved the primary endpoint in its Phase 3 trial for Reproxalap ophthalmic solution in treating dry eye disease. The company anticipates resubmitting its NDA in 2024.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am

APLS

Apellis Pharmaceuticals and Sobi announced positive Phase 3 VALIANT study results for Pegcetacoplan in treating rare kidney diseases, achieving a 68% reduction in proteinuria. The results were consistent across all subgroups, and data submission is planned for the US and EU. Apellis will host a conference call at 8:00 AM ET.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:20 am